In this study, we used nationwide registers in Sweden to assess treatment discontinuation, reinitiation and switching for GLP-1 receptor agonists and SGLT2 inhibitors in patients with type 2 diabetes. Here, GLP1R is linked to type 2 diabetes mellitus.